12A-1120828
US provisional
We used a mammalian membrane-tethered screening system (ECSTASY) to evolve human lysosomal beta-glucuronidase (hBG) to hydrolyze a glucuronide metabolite (SN-38G) of the anticancer drug irinotecan (CPT-11). Three human beta-glucuronidase variants (hBG10, hBG3 & hBG19) were identified that display up to 40-fold enhanced enzymatic activity, higher stability than E. coli beta-glucuronidase (eBG) in human serum, and similar pharmacokinetics in mice as wild-type hBG. The hBG variants were two to three orders less immunogenic than eBG in hBG transgenic mice. Intravenous administration of an antibody-hBG10 immunoenzyme targeting a sialyl-Tn tumor-associated antigen to mice bearing human colon xenografts significantly enhanced the anticancer activity of CPT-11 as measured by tumor suppression and mouse survival.
- Mammalian membrane-tethered screening system (ECSTACY) platform for selection of human enzyme variants
- More selective cancer therapy with reduced side effects
- Anti-cancer therapy
- Enzyme replacement therapy
Steve R Roffler, Chun-Hung Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Immunoenzyme for selective cancer therapy